Polyrizon (NASDAQ:PLRZ) Shares Up 11.1% – Still a Buy?

Polyrizon Ltd. (NASDAQ:PLRZ)’s share price shot up 11.1% during mid-day trading on Monday . The stock traded as high as $12.75 and last traded at $12.75. 18,708 shares traded hands during trading, a decline of 45% from the average daily volume of 34,144 shares. The stock had previously closed at $11.48.

Analyst Upgrades and Downgrades

Several research firms have commented on PLRZ. Weiss Ratings downgraded shares of Polyrizon from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday. Wall Street Zen raised shares of Polyrizon from a “sell” rating to a “hold” rating in a report on Sunday, June 7th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

Polyrizon Stock Performance

The company has a fifty day moving average of $13.85 and a two-hundred day moving average of $13.08.

Polyrizon (NASDAQ:PLRZ) last issued its quarterly earnings data on Saturday, February 14th. The company reported ($2.81) EPS for the quarter.

Institutional Investors Weigh In On Polyrizon

An institutional investor recently bought a new position in Polyrizon stock. Jane Street Group LLC purchased a new stake in Polyrizon Ltd. (NASDAQ:PLRZ) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 14,032 shares of the company’s stock, valued at approximately $119,000. Jane Street Group LLC owned approximately 1.35% of Polyrizon as of its most recent filing with the Securities & Exchange Commission.

Polyrizon Company Profile

Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.